Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
CRBP Stock Chart & Stats
$9.70
-$0.10(-0.79%)
At close: 4:00 PM EST
$9.70
-$0.10(-0.79%)
Day’s Range― - ―
52-Week Range$4.64 - $20.56
Previous CloseN/A
Volume39.58K
Average Volume (3M)503.64K
Market Cap
$128.92M
Enterprise Value-$29.96M
Total Cash (Recent Filing)$26.98M
Total Debt (Recent Filing)$2.05M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Mar 17, 2026EPS Estimate
-1.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding12,255,225
10 Day Avg. Volume744,820
30 Day Avg. Volume503,638
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio-3.08
Enterprise Value/Market Cap-0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.89
Enterprise Value/Ebitda0.44
Forecast
1Y Price Target
$44.38Price Target Upside357.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials And EfficacyThe initiation of the placebo-controlled 12-week Phase 1b CANYON-1 trial is a key development in testing CRB-913 for obesity treatment.
Financial HealthCorbus ended the third quarter with $104.0 million in cash, with an estimated pro forma cash level of about $177.8 million after the recent public offering.
Regulatory ProgressCorbus plans to discuss the data with the FDA by year-end with the intention of initiating pivotal studies by mid-2026.
Bears Say
Neuropsychiatric Event RiskThe potential for a neuropsychiatric event is expected to continue to pose as an overhang on the stock.
Safety ConcernsA key focus for investors is the safety and tolerability profile of CRB-913, with particular interest in neuropsychiatric adverse events due to historical concerns.
Weight Loss Efficacy UncertaintyThere are concerns about whether CRB-913 will demonstrate weight loss beyond the 4-6 week weight-loss plateau that plagued first generation CB-1 targeting drugs.
Corbus Pharmaceuticals News
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $4.64 and its highest was $20.56 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $128.92M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Mar 17, 2026 which is in 93 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$1.9 earnings per share for the quarter, missing the consensus estimate of -$1.657 by -$0.243.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.54.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 12,255,225 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.9 in its last earnings report, missing expectations of -$1.657. Following the earnings report the stock price went up 7.39%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in CRBP
Corbus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.38 (357.53% Upside)
$44.38 (357.53% Upside)
Hedge Fund Trend
Decreased
By 15.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.5%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.19%
12-Months-Change
Fundamentals
Return on Equity
-55.65%
Trailing 12-Months
Asset Growth
-17.70%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
CRBP Stock 12 Month Forecast
Average Price Target
$44.38
▲(357.53% Upside)
Technical Analysis
Cassava Sciences
―
Atossa Therapeutics
―
Biomea Fusion
―
TScan Therapeutics
―
HilleVax, Inc
―
Ownership Overview
8.60% Insiders
4.15% Mutual Funds
36.57% Other Institutional Investors
47.08% Public Companies and
Individual Investors